Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Complications

Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT

Bone Marrow Transplantation volume 48, pages 1456–1459 (2013)Cite this article

Subjects

Abstract

We evaluated the incidence and risk factors for hypogammaglobulinemia after allogeneic hematopoietic SCT (HSCT) in pediatric patients. Ig levels were measured pre-transplant, every 2 weeks until day 100 and then monthly post SCT in 185 patients undergoing myeloablative HSCT. Median age was 9 years; 142 (77%) had malignant disease and 114 (62%) received stem cells from an unrelated source. Hypogammaglobulinemia (IgG <500 mg/dL) developed in 143 (77%) of the patients at a median of 56 days (range 15–339) post SCT. The cumulative incidence of hypogammaglobulinemia at 1 year was higher among patients who developed acute GVHD (97% vs 54%, P<0.001), and for those receiving stem cells from an unrelated source (94% vs 51%, P<0.001). The cumulative incidence of TRM was significantly higher for patients with hypogammaglobulinemia (P=0.026). In multivariable analysis, lower pre-transplant IgG level (P<0.001), younger age (P=0.012), diagnosis of malignant disease (P<0.001), receiving unrelated SCT (P<0.001) and development of acute GVHD (P<0.001) were all significantly associated with higher risk of hypogammaglobulinemia post HSCT. We conclude that hypogammaglobulinemia is common, following allogeneic HSCT in pediatric patients, especially in those with malignant diseases, those who receive an unrelated transplant or patients who develop GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Geddes M, Storek J . Immune reconstitution following hematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007; 20: 329–348.

    Article  CAS  Google Scholar 

  2. Storek J, Wells D, Dawson MA, Storer B, Maloney DG . Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 489–491.

    Article  CAS  Google Scholar 

  3. Norlin AC, Sairafi D, Mattsson J, Ljungman P, Ringden O, Remberger M . Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 2008; 41: 267–273.

    Article  CAS  Google Scholar 

  4. Wils EJ, Cornelissen JJ . Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. Blood Rev 2005; 19: 89–98.

    Article  Google Scholar 

  5. Storek J, Viganego F, Dawson MA, Herremans MM, Boeckh M, Flowers ME et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 2003; 101: 3319–3324.

    Article  CAS  Google Scholar 

  6. Cordonnier C, Chevret S, Legrand M, Rafi H, Dhedin N, Lehmann B et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003; 139: 8–18.

    Article  CAS  Google Scholar 

  7. Feinstein LC, Seidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant 1999; 5: 369–378.

    Article  CAS  Google Scholar 

  8. Howell JE, Gulbis AM, Champlin RE, Qazilbash MH . Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol 2011; 87: 172–174.

    Article  Google Scholar 

  9. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA . Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 1990; 75: 1583–1586.

    CAS  PubMed  Google Scholar 

  10. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705–712.

    Article  CAS  Google Scholar 

  11. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2: 44–53.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Alisha McCord for the administrative support. This project was supported by the Carolyn Perot Rathjen Chair in Pediatrics, Nashville, TN, USA (Haydar Frangoul).

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt University, Monroe Carell Jr Children’s Hospital at Vanderbilt, Nashville, TN, USA

    H Frangoul, C Calder, M Evans, B Manes, V Brown, R Ho & J Domm

  2. Vanderbilt School of Medicine, Nashville, TN, USA

    E Min

  3. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA

    W Wang & R Chandrasekhar

  4. Department of Pharmacy, Vanderbilt University, Nashville, TN, USA

    K Bruce

Authors
  1. H Frangoul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Chandrasekhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Calder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Manes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Bruce
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Domm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Frangoul.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frangoul, H., Min, E., Wang, W. et al. Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transplant 48, 1456–1459 (2013). https://doi.org/10.1038/bmt.2013.76

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.76

Keywords

This article is cited by

Search

Advanced search

Quick links